Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella

ABSTRACT Shigella is a leading cause of diarrheal morbidity and mortality in young children from low- and middle-income countries. Here, we aimed to verify the ability of the generalized modules for membrane antigens (GMMA)-based Shigella sonnei candidate vaccine 1790GAHB to elicit an anti-protein a...

Full description

Saved in:
Bibliographic Details
Main Authors: Arlo Z. Randall, Valentino Conti, Usman Nakakana, Xiaowu Liang, Andy A. Teng, Antonio Lorenzo Di Pasquale, Melissa Kapulu, Robert Frenck, Odile Launay, Pietro Ferruzzi, Antonella Silvia Sciré, Elisa Marchetti, Christina Obiero, Jozelyn V. Pablo, Joshua Edgar, Philip Bejon, Adam D. Shandling, Joseph J. Campo, Angela Yee, Laura B. Martin, Audino Podda, Francesca Micoli
Format: Article
Language:English
Published: American Society for Microbiology 2025-05-01
Series:mSphere
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/msphere.01057-24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849327649414971392
author Arlo Z. Randall
Valentino Conti
Usman Nakakana
Xiaowu Liang
Andy A. Teng
Antonio Lorenzo Di Pasquale
Melissa Kapulu
Robert Frenck
Odile Launay
Pietro Ferruzzi
Antonella Silvia Sciré
Elisa Marchetti
Christina Obiero
Jozelyn V. Pablo
Joshua Edgar
Philip Bejon
Adam D. Shandling
Joseph J. Campo
Angela Yee
Laura B. Martin
Audino Podda
Francesca Micoli
author_facet Arlo Z. Randall
Valentino Conti
Usman Nakakana
Xiaowu Liang
Andy A. Teng
Antonio Lorenzo Di Pasquale
Melissa Kapulu
Robert Frenck
Odile Launay
Pietro Ferruzzi
Antonella Silvia Sciré
Elisa Marchetti
Christina Obiero
Jozelyn V. Pablo
Joshua Edgar
Philip Bejon
Adam D. Shandling
Joseph J. Campo
Angela Yee
Laura B. Martin
Audino Podda
Francesca Micoli
author_sort Arlo Z. Randall
collection DOAJ
description ABSTRACT Shigella is a leading cause of diarrheal morbidity and mortality in young children from low- and middle-income countries. Here, we aimed to verify the ability of the generalized modules for membrane antigens (GMMA)-based Shigella sonnei candidate vaccine 1790GAHB to elicit an anti-protein antibody response. Serum samples from previous clinical trials in adults (a dose-escalation study and its extension in France, a vaccine efficacy study after human challenge in the United States, and a study in Kenya) were investigated using pan-proteome microarrays consisting of 3,150 full-length or fragmented Shigella proteins. Pre-/post-vaccination comparisons identified subsets of proteins that were highly immunoreactive and largely overlapped across all trials; the T3SS lipochaperone family protein (expressed on GMMA) was the most reactive in all studies. Responses to several microarray antigens correlated well with S. sonnei LPS serum IgG antibody levels. Overall, we confirmed the ability of GMMA to elicit an anti-protein IgG/IgA response; however, no association with protection against shigellosis was identified. In the challenge study, IgG response to seven antigens (IpaC, IpaB, IpaA, IpaD, IpaH, IpgC, and MxiD; not expressed on GMMA) was associated with a decreased risk of shigellosis. These antigens were observed to also have high IgG responses at baseline in individuals naturally exposed to Shigella and could constitute targets for future vaccine development.IMPORTANCEShigella remains a major cause of diarrheal disease, especially in children aged under 5 years from low-to-middle-income countries. No vaccine against shigellosis is yet widely available despite the high public health need. An ideal vaccine would provide protection against the most prevalent species, Shigella flexneri and Shigella sonnei; therefore, it could be relevant to identify common antigens. We developed a microarray containing 3,150 full-length or fragmented proteins selected across Shigella species. Sera collected in four clinical trials conducted in three countries of varying endemicity to evaluate a S. sonnei GMMA-based candidate vaccine were tested against these proteins. We identified several Shigella proteins (IpaC, IpaB, IpaA, IpaD, IpaH, IpgC, MxiD) that induced robust antibody response following experimental challenge or natural infection. These proteins correlated with a reduced risk of shigellosis after the S. sonnei challenge. We found no apparent role for anti-GMMA proteins’ IgG or IgA response in protection against shigellosis.
format Article
id doaj-art-5fd2b32479a347c9ac8e0335f45cf2cd
institution Kabale University
issn 2379-5042
language English
publishDate 2025-05-01
publisher American Society for Microbiology
record_format Article
series mSphere
spelling doaj-art-5fd2b32479a347c9ac8e0335f45cf2cd2025-08-20T03:47:49ZengAmerican Society for MicrobiologymSphere2379-50422025-05-0110510.1128/msphere.01057-24Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to ShigellaArlo Z. Randall0Valentino Conti1Usman Nakakana2Xiaowu Liang3Andy A. Teng4Antonio Lorenzo Di Pasquale5Melissa Kapulu6Robert Frenck7Odile Launay8Pietro Ferruzzi9Antonella Silvia Sciré10Elisa Marchetti11Christina Obiero12Jozelyn V. Pablo13Joshua Edgar14Philip Bejon15Adam D. Shandling16Joseph J. Campo17Angela Yee18Laura B. Martin19Audino Podda20Francesca Micoli21Antigen Discovery, Inc. (ADI), Irvine, California, USAGSK Vaccines Institute for Global Health, Siena, ItalyGSK Vaccines Institute for Global Health, Siena, ItalyAntigen Discovery, Inc. (ADI), Irvine, California, USAAntigen Discovery, Inc. (ADI), Irvine, California, USAGSK Vaccines Institute for Global Health, Siena, ItalyBiosciences Department, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, KenyaDivision of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USAUniversité Paris Cité; Assistance Publique Hôpitaux de Paris, CIC Cochin Pasteur; Inserm, Paris, FranceGSK Vaccines Institute for Global Health, Siena, ItalyGSK Vaccines Institute for Global Health, Siena, ItalyGSK Vaccines Institute for Global Health, Siena, ItalyClinical Research Department, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, KenyaAntigen Discovery, Inc. (ADI), Irvine, California, USAAntigen Discovery, Inc. (ADI), Irvine, California, USABiosciences Department, Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, KenyaAntigen Discovery, Inc. (ADI), Irvine, California, USAAntigen Discovery, Inc. (ADI), Irvine, California, USAAntigen Discovery, Inc. (ADI), Irvine, California, USAGSK Vaccines Institute for Global Health, Siena, ItalyGSK Vaccines Institute for Global Health, Siena, ItalyGSK Vaccines Institute for Global Health, Siena, ItalyABSTRACT Shigella is a leading cause of diarrheal morbidity and mortality in young children from low- and middle-income countries. Here, we aimed to verify the ability of the generalized modules for membrane antigens (GMMA)-based Shigella sonnei candidate vaccine 1790GAHB to elicit an anti-protein antibody response. Serum samples from previous clinical trials in adults (a dose-escalation study and its extension in France, a vaccine efficacy study after human challenge in the United States, and a study in Kenya) were investigated using pan-proteome microarrays consisting of 3,150 full-length or fragmented Shigella proteins. Pre-/post-vaccination comparisons identified subsets of proteins that were highly immunoreactive and largely overlapped across all trials; the T3SS lipochaperone family protein (expressed on GMMA) was the most reactive in all studies. Responses to several microarray antigens correlated well with S. sonnei LPS serum IgG antibody levels. Overall, we confirmed the ability of GMMA to elicit an anti-protein IgG/IgA response; however, no association with protection against shigellosis was identified. In the challenge study, IgG response to seven antigens (IpaC, IpaB, IpaA, IpaD, IpaH, IpgC, and MxiD; not expressed on GMMA) was associated with a decreased risk of shigellosis. These antigens were observed to also have high IgG responses at baseline in individuals naturally exposed to Shigella and could constitute targets for future vaccine development.IMPORTANCEShigella remains a major cause of diarrheal disease, especially in children aged under 5 years from low-to-middle-income countries. No vaccine against shigellosis is yet widely available despite the high public health need. An ideal vaccine would provide protection against the most prevalent species, Shigella flexneri and Shigella sonnei; therefore, it could be relevant to identify common antigens. We developed a microarray containing 3,150 full-length or fragmented proteins selected across Shigella species. Sera collected in four clinical trials conducted in three countries of varying endemicity to evaluate a S. sonnei GMMA-based candidate vaccine were tested against these proteins. We identified several Shigella proteins (IpaC, IpaB, IpaA, IpaD, IpaH, IpgC, MxiD) that induced robust antibody response following experimental challenge or natural infection. These proteins correlated with a reduced risk of shigellosis after the S. sonnei challenge. We found no apparent role for anti-GMMA proteins’ IgG or IgA response in protection against shigellosis.https://journals.asm.org/doi/10.1128/msphere.01057-24protein microarrayproteome immune profilingShigellavaccineGeneralized Modules for Membrane Antigens (GMMA)
spellingShingle Arlo Z. Randall
Valentino Conti
Usman Nakakana
Xiaowu Liang
Andy A. Teng
Antonio Lorenzo Di Pasquale
Melissa Kapulu
Robert Frenck
Odile Launay
Pietro Ferruzzi
Antonella Silvia Sciré
Elisa Marchetti
Christina Obiero
Jozelyn V. Pablo
Joshua Edgar
Philip Bejon
Adam D. Shandling
Joseph J. Campo
Angela Yee
Laura B. Martin
Audino Podda
Francesca Micoli
Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
mSphere
protein microarray
proteome immune profiling
Shigella
vaccine
Generalized Modules for Membrane Antigens (GMMA)
title Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
title_full Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
title_fullStr Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
title_full_unstemmed Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
title_short Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella
title_sort protein specific immune response elicited by the shigella sonnei 1790gahb gmma based candidate vaccine in adults with varying exposure to shigella
topic protein microarray
proteome immune profiling
Shigella
vaccine
Generalized Modules for Membrane Antigens (GMMA)
url https://journals.asm.org/doi/10.1128/msphere.01057-24
work_keys_str_mv AT arlozrandall proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT valentinoconti proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT usmannakakana proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT xiaowuliang proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT andyateng proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT antoniolorenzodipasquale proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT melissakapulu proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT robertfrenck proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT odilelaunay proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT pietroferruzzi proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT antonellasilviascire proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT elisamarchetti proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT christinaobiero proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT jozelynvpablo proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT joshuaedgar proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT philipbejon proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT adamdshandling proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT josephjcampo proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT angelayee proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT laurabmartin proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT audinopodda proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella
AT francescamicoli proteinspecificimmuneresponseelicitedbytheshigellasonnei1790gahbgmmabasedcandidatevaccineinadultswithvaryingexposuretoshigella